Clinical Data ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH Pharmaceutical TechnologyNew data presented at ACC 2026 clarifies sotatercept's role alongside vasodilator-based regimens in PAH patients.Clinical DataCardiovascularRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaceutical Technology New data presented at ACC 2026 clarifies sotatercept’s role alongside vasodilator-based regimens in PAH patients. Clinical DataCardiovascularRead full story Post navigation Previous: Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is ChillingNext: Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
